rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CHRS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Down 49.7% in 4 Weeks, Here's Why Coherus Oncology (CHRS) Looks Ripe for a Turnaround
      Nov 13Yahoo FinanceCHRS
      Oncolytics enters supply deal with Coherus for cancer study
      Nov 11Investing.comCHRSONCY
      Coherus Oncology Inc (CHRS) (Q3 2026) Earnings Call Highlights: Cost Cuts, Loqtorzi Growth and ...

      Coherus Oncology Inc (CHRS) trimmed headcount by 30% and lowered its breakeven threshold while revising 2026 Loqtorzi guidance to $54-$57 million amid a sub-12-month cash runway.

      Nov 10Yahoo FinanceCHRS
      Coherus Oncology: 3 Key Takeaways for Long-Term Investors
      Nov 10Yahoo FinanceCHRS
      What Coherus Oncology (CHRS) Said on Its Q3 Earnings Call
      Nov 10Yahoo FinanceCHRS
      Earnings call transcript: Coherus BioSciences posts Q3 2026 revenue miss, shares rise
      Nov 9Investing.comCHRS
      Coherus BioSciences Q3 2026 Earnings Call Transcript
      Nov 9BenzingaCHRS
      Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
      Nov 9Yahoo FinanceCHRS
      Coherus Oncology: Q3 Earnings Snapshot
      Nov 9Yahoo FinanceCHRS
      Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer - Slideshow (NASDAQ:CHRS) 2026-11-02

      2026-11-02. The following slide deck was published by Coherus Oncology, Inc.

      Nov 2Seeking AlphaCHRS
      Will Coherus Oncology (CHRS) Report Negative Earnings Next Week? What You Should Know
      Nov 2Yahoo FinanceCHRS
      Coherus Biosciences stock rating maintained at Outperform by Oppenheimer
      Oct 29Investing.comCHRSOPY
      Coherus Oncology Reports 89% Response Rate in Early ESCC Study
      Oct 29Yahoo FinanceCHRS
      Coherus releases promising early-stage data on tagmokitug in esophageal cancer
      Oct 28Seeking AlphaCHRS
      Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
      Oct 28Yahoo FinanceCHRS
      Coherus to Participate in Upcoming Investor Conferences

      REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 10, 2026, at 7:30 a.m. Eastern Daylight Time.Jefferies Global Healthcare Conference in London, UK on Monday, November 16, 2026, at 10:30 a.m. Greenwich Mountain Time / 5:30 a.m. Eastern Daylight Ti

      Oct 27Yahoo FinanceCHRS
      Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
      Oct 26Yahoo FinanceCHRS
      Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

      REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab in multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion le

      Oct 14Yahoo FinanceCHRS
      Coherus initiates sale of legacy biosimilars assets
      Sep 23Investing.comCHRS
      Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets

      Coherus Oncology (CHRS) said Wednesday it has begun the process to sell remaining assets related to

      Sep 23Yahoo FinanceCHRS
      Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
      Sep 23Yahoo FinanceCHRS
      Coherus at Morgan Stanley healthcare conference: oncology push gains traction
      Sep 16Investing.comCHRSMS
      Coherus Oncology at 2026 Global Healthcare Conference: pipeline, sales push
      Sep 15Investing.comCHRS
      Coherus to Participate in Upcoming Investor Conferences

      REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences: Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.Morgan Stanley 24th Annual Global Healthcare Confere

      Aug 31Yahoo FinanceCHRS

      This is the newest page. Registered accounts read further back.